Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$0.54 - $10.3 $1,934 - $36,904
-3,583 Reduced 1.16%
304,246 $176,000
Q3 2022

Nov 14, 2022

SELL
$0.96 - $9.68 $16,569 - $167,076
-17,260 Reduced 5.31%
307,829 $292,000
Q2 2022

Aug 15, 2022

BUY
$0.81 - $1.34 $31,407 - $51,958
38,775 Added 13.54%
325,089 $390,000
Q1 2022

May 16, 2022

BUY
$1.23 - $1.95 $320,059 - $507,411
260,211 Added 996.86%
286,314 $375,000
Q4 2021

Feb 14, 2022

SELL
$1.74 - $2.4 $20,095 - $27,717
-11,549 Reduced 30.67%
26,103 $46,000
Q3 2021

Nov 15, 2021

SELL
$2.08 - $3.6 $4,078 - $7,059
-1,961 Reduced 4.95%
37,652 $82,000
Q2 2021

Aug 17, 2021

BUY
$3.36 - $10.56 $47,087 - $147,987
14,014 Added 54.74%
39,613 $138,000
Q1 2021

May 17, 2021

SELL
$9.26 - $14.36 $27,122 - $42,060
-2,929 Reduced 10.27%
25,599 $252,000
Q4 2020

Feb 16, 2021

BUY
$9.84 - $14.26 $128,008 - $185,508
13,009 Added 83.83%
28,528 $310,000
Q3 2020

Nov 16, 2020

SELL
$10.3 - $21.64 $4.05 Million - $8.51 Million
-393,382 Reduced 96.2%
15,519 $160,000
Q2 2020

Aug 14, 2020

BUY
$8.53 - $25.64 $123,062 - $369,908
14,427 Added 3.66%
408,901 $8.54 Million
Q1 2020

May 15, 2020

BUY
$7.98 - $16.32 $1.81 Million - $3.7 Million
226,860 Added 135.35%
394,474 $3.85 Million
Q4 2019

Feb 14, 2020

BUY
$5.12 - $12.22 $580,910 - $1.39 Million
113,459 Added 209.51%
167,614 $1.93 Million
Q3 2019

Nov 14, 2019

SELL
$5.24 - $15.89 $1.27 Million - $3.86 Million
-243,166 Reduced 81.79%
54,155 $296,000
Q2 2019

Aug 14, 2019

BUY
$5.1 - $11.89 $1.26 Million - $2.94 Million
246,913 Added 489.83%
297,321 $3.54 Million
Q1 2019

May 15, 2019

BUY
$3.03 - $6.02 $10,895 - $21,647
3,596 Added 7.68%
50,408 $264,000
Q4 2018

Feb 14, 2019

BUY
$2.87 - $5.92 $134,350 - $277,127
46,812 New
46,812 $147,000

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.